Stock Screener App
Gratuito
-
Play Store
App Store
Installare
Installare
Dark
IT
Sign in
Lista di controllo
Liste migliori
Mercati
Nuovo
Criptovalute
Industrie
Elite
Simulatore di mercato
Dow:
Nasdaq:
S&P 500:
Pagina iniziale
›
NASDAQ: AMRN
›
Notizia
AMRN
$12.11
4.91%
-0.625
Amarin Corp Adr (AMRN)
Indicatore
1D
1W
1M
6M
YTD
1Y
5Y
MAX
Line
Candle
SMA
RSI
BB
Date:
2026-10-30 16:00
O:
12.71
H:
12.76
L:
12.00
C:
12.11
Vol:
101.3k
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Finanziari
Forum
Previsione
Frazionamento azionario
Amarin Corp Adr Borsa (AMRN) Ultime notizie
Oct 29, 2026
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
- Zacks Investment Research
Oct 29, 2026
Oct 27, 2026
Amarin (AMRN) Set to Report Q3 Earnings Amid Price-to-Sales Valu
- GuruFocus
Oct 27, 2026
Oct 26, 2026
Amarin Corporation PLC expected to post a loss of 2 cents a share - Earnings Preview
- TradingView
Oct 26, 2026
Oct 25, 2026
Amarin’s icosapent ethyl shows survival benefit in cancer trial
- Investing.com
Oct 25, 2026
Oct 25, 2026
Amarin Highlights EMT2 Phase 3 Trial Showing Overall Survival Benefit for VAZKEPA/VASCEPA in Colorectal Cancer Liver Metastases
- Quiver Quantitative
Oct 25, 2026
Oct 25, 2026
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal
- The Manila Times
Oct 25, 2026
Oct 25, 2026
A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.
- Stock Titan
Oct 25, 2026
Oct 25, 2026
Amarin’s icosapent ethyl shows survival benefit in cancer trial By Investing.com
- Investing.com UK
Oct 25, 2026
Oct 23, 2026
Amarin Corporation Plc Sponsored ADR Estimates – SWB:EH3
- TradingView
Oct 23, 2026
Oct 21, 2026
Amarin Announces Date for Third Quarter 2026 Financial Results Conference Call
- Moomoo
Oct 21, 2026
Oct 21, 2026
Amarin Announces Date for Third Quarter 2026 Financial Results Conference Call
- Quiver Quantitative
Oct 21, 2026
Oct 21, 2026
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
- Yahoo Finance
Oct 21, 2026
Oct 21, 2026
Third-quarter results are due before market hours Oct. 28, followed by Amarin's 8 a.m. ET call.
- Stock Titan
Oct 21, 2026
Oct 17, 2026
Amarin Q2 2026 Earnings: $0.04 Per Share Swings to Profit, Beating Estimates by 492% - EBITDA Analysis
- https://www.dars.gov.et/
Oct 17, 2026
Oct 17, 2026
Amarin Q2 2026 Earnings: $0.04 Per Share Swings to Profit, Beating Estimates by 492% - Preliminary Results
- https://www.dars.gov.et/
Oct 17, 2026
Oct 15, 2026
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
- Zacks Investment Research
Oct 15, 2026
Oct 15, 2026
Here's Why You Should Add EYPT Stock to Your Portfolio Now
- Zacks Investment Research
Oct 15, 2026
Oct 15, 2026
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
- Zacks Investment Research
Oct 15, 2026
Oct 14, 2026
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
- Zacks Investment Research
Oct 14, 2026
Oct 14, 2026
Here's Why You Should Add ANRO Stock to Your Portfolio Now
- Zacks Investment Research
Oct 14, 2026
Oct 14, 2026
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
- Zacks Investment Research
Oct 14, 2026
Oct 13, 2026
BMY Reports Mixed Phase III Trial Results, Stock Down
- Zacks Investment Research
Oct 13, 2026
Oct 12, 2026
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
- Zacks Investment Research
Oct 12, 2026
Oct 12, 2026
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
- Zacks Investment Research
Oct 12, 2026
Oct 09, 2026
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
- Zacks Investment Research
Oct 09, 2026
Oct 09, 2026
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
- Zacks Investment Research
Oct 09, 2026
Oct 09, 2026
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
- TradingView
Oct 09, 2026
Oct 08, 2026
Here's Why You Should Add LPCN Stock to Your Portfolio Now
- Zacks Investment Research
Oct 08, 2026
Oct 07, 2026
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
- Zacks Investment Research
Oct 07, 2026
Oct 06, 2026
Amarin (AMRN) Slips 2.11% to $12.09 as Shares Test Lower End of Recent Range - Corrective Wave
- https://www.siam.in/
Oct 06, 2026
Oct 03, 2026
Amarin Corporation (AMRN) Slips 2.91% to $12.35 as Traders Eye Support at $11.73 - Diagonal Spread Trade
- https://www.dars.gov.et/
Oct 03, 2026
Oct 01, 2026
Amarin Corporation plc (AMRN) Options Chain
- Yahoo! Finance Canada
Oct 01, 2026
Oct 01, 2026
Amarin Corporation plc (AMRN) Stock Price, News, Quote & History
- Yahoo! Finance Canada
Oct 01, 2026
Oct 01, 2026
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
- Zacks Investment Research
Oct 01, 2026
Sep 25, 2026
Amarin Stock Price Forecast. Should You Buy AMRN?
- StockInvest.us
Sep 25, 2026
Sep 24, 2026
Amarin Corporation plc (AMRN) Options Chain - Yahoo Finance
- Yahoo! Finance Canada
Sep 24, 2026
Sep 24, 2026
Amarin Corporation plc (AMRN) Options Chain - Yahoo Finance
- Yahoo! Finance Canada
Sep 24, 2026
Sep 10, 2026
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
- Zacks Investment Research
Sep 10, 2026
Sep 09, 2026
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
- Yahoo Finance
Sep 09, 2026
Aug 31, 2026
Amarin Highlights New ESC 2026 Data and Guideline Support Reinforcing Evidence for Icosapent Ethyl
- Quiver Quantitative
Aug 31, 2026
Aug 30, 2026
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ)
- Seeking Alpha
Aug 30, 2026
Aug 28, 2026
Heart treatment linked to ~30% fewer major events; benefits may persist after stopping
- Stock Titan
Aug 28, 2026
Aug 27, 2026
Amarin (NASDAQ: AMRN) sees Sarissa report 25.7M+ shares
- Stock Titan
Aug 27, 2026
Aug 24, 2026
Amarin Announces REDUCE-IT-Related Presentations at ESC Congress 2026 in Munich
- Quiver Quantitative
Aug 24, 2026
Aug 24, 2026
Five abstracts from an 8,179-patient study are set for the 2026 heart congress
- Stock Titan
Aug 24, 2026
Aug 17, 2026
Amarin (AMRN) Holds Near $14.15 as Bulls Defend Key Support Zone - Momentum Stock Picks
- careplusvn.com
Aug 17, 2026
Aug 15, 2026
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – LSX:A41557
- TradingView
Aug 15, 2026
Jul 29, 2026
Earnings call transcript: Amarin Q2 2026 revenue falls, but cash flow improves
- Investing.com
Jul 29, 2026
Jul 29, 2026
Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges
- Yahoo Finance
Jul 29, 2026
Jul 29, 2026
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
- TradingView
Jul 29, 2026
Simile a AMRN
NSRX
$3.07
3.76%
MIRA
$0.5485
4.04%
SCLX
$1.85
10.19%
MDCX
$1.88
12.56%
OGN
$13.84
0.22%
GRFS
$8.10
0.75%
Apri in Yahoo
|
Apri in Google
|
Apri in Finviz
|
Apri in MarketWatch
|
Apri in EDGAR
|
Apri in Reuters